Advertisement

Seltene Erkrankungen an der Haut erkennen

  • Bruno Gualtieri
  • Michael Hertl
Seltene Erkrankungen
  • 63 Downloads

Zusammenfassung

Die korrekte Interpretation von Hauterscheinungen kann die Diagnose zahlreicher seltener systemischer Erkrankungen erleichtern. Solchen Manifestationen können sowohl Autoimmunerkrankungen (Dermatomyositis, systemischer Lupus erythematodes, systemische Sklerodermie, Sarkoidose) als auch Stoffwechselerkrankungen (Porphyria cutanea tarda, Anderson-Fabry-Krankheit) zugrunde liegen. Andere Hauterscheinungen sind von großer Wichtigkeit, weil sie mögliche Warnzeichen okkulter Erkrankungen der inneren Organe sind. Dies gilt beispielsweise für einige Erkrankungen aus der Gruppe der neutrophilen Dermatosen (Pyoderma gangraenosum, Sweet-Syndrom).

Schlüsselwörter

Hautzeichen innerer Erkrankungen Autoimmunerkrankungen Stoffwechselerkrankungen Sweet-Syndrom Livedo reticularis 

Recognize rare diseases on the skin

Abstract

The correct interpretation of skin manifestations can facilitate the diagnosis of many rare systemic diseases. Such manifestations can be due to autoimmune diseases (e.g. dermatomyositis, systemic lupus erythematosus, systemic sclerosis and sarcoidosis) and metabolic diseases (e.g. Anderson-Fabry disease and porphyria cutanea tarda). Other cutaneous symptoms are of great importance because they are possible warning signs of occult diseases of internal organs. This is true for example for some diseases from the group of neutrophilic dermatoses, such as Sweet’s syndrome and pyoderma gangraenosum.

Keywords

Skin manifestations, internal diseases Autoimmune diseases Metabolic diseases Sweet’s syndrome Livedo reticularis 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

B. Gualtieri und M. Hertl geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.

Literatur

  1. 1.
    Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14(5):269–278PubMedCrossRefGoogle Scholar
  2. 2.
    Marvi U, Chung L, Fiorentino DF (2012) Clinical presentation and evaluation of dermatomyositis. Indian J Dermatol 57(5):375–381PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Zahr ZA, Baer AN (2011) Malignancy in myositis. Curr Rheumatol Rep 13:208–215PubMedCrossRefGoogle Scholar
  4. 4.
    Kuhn A, Gensch K, Ständer S, Bonsmann G (2006) Cutaneous lupus erythematosus. Part 1: clinical manifestations and classification. Hautarzt 57(3):251–267PubMedCrossRefGoogle Scholar
  5. 5.
    Kuhn A, Landmann A (2014) The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun 48–49:14–19PubMedCrossRefGoogle Scholar
  6. 6.
    Vanoni F, Lava SAG, Fossali EF et al (2017) Neonatal systemic lupus erythematosus syndrome: a comprehensive review. Clin Rev Allergy Immunol 53(3):469–476PubMedCrossRefGoogle Scholar
  7. 7.
    Inzinger M, Salmhofer W, Binder B (2012) Neonatal lupus erythematosus and its clinical variability. J Dtsch Dermatol Ges 10(6):407–411PubMedGoogle Scholar
  8. 8.
    Hasbún T, Chamlin SL (2014) A 6‑week-old boy with annular skin lesions. Neonatal lupus erythematosus. Pediatr Ann 43(1):e1–e3PubMedCrossRefGoogle Scholar
  9. 9.
    Alavi A, Sajic D, Cerci FB et al (2014) Neutrophilic dermatoses: an update. Am J Clin Dermatol 15(5):413–423PubMedCrossRefGoogle Scholar
  10. 10.
    Kridin K, Cohen AD, Amber KT (2018) Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol 19(4):479–487PubMedCrossRefGoogle Scholar
  11. 11.
    Rochet NM, Chavan RN, Cappel MA, Wada DA, Gibson LE (2013) Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol 69(4):557–564PubMedCrossRefGoogle Scholar
  12. 12.
    Grignano E, Jachiet V, Fenaux P et al (2018) Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol 97(11):2015–2023.  https://doi.org/10.1007/s00277-018-3472-9 PubMedCrossRefGoogle Scholar
  13. 13.
    Hindryckx P, Novak G, Costanzo A, Danese S (2017) Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 11(3):203–214PubMedGoogle Scholar
  14. 14.
    Tchernev G (2006) Cutaneous sarcoidosis: the „great imitator“: etiopathogenesis, morphology, differential diagnosis, and clinical management. Am J Clin Dermatol 7(6):375–382PubMedCrossRefGoogle Scholar
  15. 15.
    Saltman AP, Kuriya B (2017) Löfgren syndrome in acute sarcoidosis. CMAJ 189(39):E1230PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Fernandez-Faith E, McDonnell J (2007) Cutaneous sarcoidosis: differential diagnosis. Clin Dermatol 25(3):276–287PubMedCrossRefGoogle Scholar
  17. 17.
    Simunovic C, Shinohara MM (2014) Complications of decorative tattoos: recognition and management. Am J Clin Dermatol 15(6):525–536PubMedCrossRefGoogle Scholar
  18. 18.
    Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL (2017) Points to consider-Raynaud’s phenomenon in systemic sclerosis. Rheumatology (Oxf) 56(suppl 5):v45–v48CrossRefGoogle Scholar
  19. 19.
    Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685–1699PubMedCrossRefGoogle Scholar
  20. 20.
    Ferreli C, Gasparini G, Parodi A et al (2017) Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol 53(3):306–336PubMedCrossRefGoogle Scholar
  21. 21.
    Sangle SR, D’Cruz DP (2015) Livedo reticularis: an enigma. Isr Med Assoc J 17(2):104–107PubMedGoogle Scholar
  22. 22.
    Medlin JL, Hansen KE, Fitz SR, Bartels CM (2016) A systematic review and meta-analysis of cutaneous manifestations in late- versus early-onset systemic lupus erythematosus. Semin Arthritis Rheum 45(6):691–697PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Wu S, Xu Z, Liang H (2014) Sneddon’s syndrome: a comprehensive review of the literature. Orphanet J Rare Dis 9:215PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Shrikrishnapalasuriyar N, Noyvirt M, Evans P et al (2018) Livedo reticularis: a cutaneous clue to an underlying endocrine crisis. Endocrinol Diabetes Metab Case Rep.  https://doi.org/10.1530/edm-17-0170 PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Vasudevan B, Verma R, Pragasam V, Badad A (2014) Livedo reticularis due to pellagra in a two year old child. Indian J Dermatol 59(3):317PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Quaresma MV, Gomes AC, Serruya A et al (2015) Amantadine-induced livedo reticularis—case report. An Bras Dermatol 90(5):745–747PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Thornsberry LA, LoSicco KI, English JC 3rd (2013) The skin and hypercoagulable states. J Am Acad Dermatol 69(3):450–462PubMedCrossRefGoogle Scholar
  28. 28.
    Marzano AV, Vezzoli P, Berti E (2013) Skin involvement in cutaneous and systemic vasculitis. Autoimmun Rev 12(4):467–476PubMedCrossRefGoogle Scholar
  29. 29.
    Kerk N, Goerge T (2013) Livedoid vasculopathy—a thrombotic disease. Vasa 42(5):317–322PubMedCrossRefGoogle Scholar
  30. 30.
    Tuttolomondo A, Pecoraro R, Simonetta I et al (2013) Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des 19(33):5974–5996PubMedCrossRefGoogle Scholar
  31. 31.
    Giuseppe P, Daniele R, Rita BM (2013) Cutaneous complications of Anderson-Fabry disease. Curr Pharm Des 19(33):6031–6036PubMedCrossRefGoogle Scholar
  32. 32.
    Bissell DM, Anderson KE, Bonkovsky HL (2017) Porphyria. N Engl J Med 377(9):862–872PubMedCrossRefGoogle Scholar
  33. 33.
    Kranzelbinder B, Wiednig M, El-Shabrawi-Caelen L, Aberer W, Aberer E (2015) Sclerodermiform porphyria cutanea tarda after torasemide. Eur J Dermatol 25(5):484–485PubMedGoogle Scholar
  34. 34.
    Handler NS, Handler MZ, Stephany MP, Handler GA, Schwartz RA (2017) Porphyria cutanea tarda: an intriguing genetic disease and marker. Int J Dermatol 56(6):e106–e117PubMedCrossRefGoogle Scholar
  35. 35.
    Markova A, Lester J, Wang J, Robinson-Bostom L (2012) Diagnosis of common dermopathies in dialysis patients: a review and update. Semin Dial 25(4):408–418PubMedCrossRefGoogle Scholar
  36. 36.
    Guiotoku MM, Pereira Fde P, Miot HA, Marques ME (2011) Pseudoporphyria induced by dialysis treated with oral N‑acetylcysteine. An Bras Dermatol 86(2):383–385PubMedCrossRefGoogle Scholar
  37. 37.
    Conde Fernandes I, Sanches M, Velho G et al (2011) Scleromyxedema vs scleredema: a diagnostic challenge. Eur J Dermatol 21(5):822–823PubMedGoogle Scholar
  38. 38.
    Kreuter A (2018) Scleredema adultorum: clinical presentation, diagnostic workup, differential diagnosis, treatment option. Hautarzt.  https://doi.org/10.1007/s00105-018-4259-6 PubMedCrossRefGoogle Scholar
  39. 39.
    Cron RQ, Swetter SM (1994) Scleredema revisited. A poststreptococcal complication. Clin Pediatr (Phila).  https://doi.org/10.1177/000992289403301006 CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Dermatologie und AllergologieUniversitätsklinikum Marburg (UKGM)MarburgDeutschland

Personalised recommendations